CeriBell, Inc. (CBLL) SEC Filings & Earnings Calls
EquiReason read 15 CeriBell, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-10 — Quarterly report filed with updated financials; no earnings beat or miss stated..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
10 Aug 202610-QQuarterly report filed with updated financials; no earnings beat or miss stated.earningsopen
Figures in the filing · each found in the filing text
| Net loss · H1-2026 | $-39M | |
| Accumulated deficit · 2026-06-30 | $259M |
Risks flagged
Single product dependency
“We expect that revenue from sales of the Ceribell System will continue to account for almost all of our revenue for the foreseeable future.” · word for word
Customer termination risk
“Existing customers may choose to terminate or not renew their subscription typically on 30 days’ notice to us without payment of a penalty or termination fee” · word for word
Algorithm performance risk
“Villamar et al. (2023) ... found that the Clarity algorithm ... did not detect seizures in the four patients who were experiencing them.” · word for word
Tariff and supply chain risk
“We rely on manufacturing facilities and third-party suppliers outside the United States, including in China and Vietnam, for the primary assembly and inspection of our Wearables and for a significant portion of our components.” · word for word
Reimbursement risk
“If adequate reimbursement becomes unavailable for the diagnostic tests using our products, it could diminish our sales or affect our ability to sell the Ceribell System profitably.” · word for word
10 Aug 20268-K · 2.02Total revenue $28M (+33% y/y); Product revenue $21M (+33% y/y); Subscription revenue $7M (+30% y/y); Guidance: Revenue guidance raised to $114-117M from prior rangeearningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $28M | +33% y/y |
| Product revenue · Product · Q2-2026 | $21M | +33% y/y |
| Subscription revenue · Subscription · Q2-2026 | $7M | +30% y/y |
| Gross margin · Q2-2026 | 92.0% | |
| Active accounts · Q2-2026 | 712 | |
| Net loss · Q2-2026 | $-19M | +42% y/y |
| Adjusted EBITDA loss · Q2-2026 | $-10M | -2% y/y |
| Cash, cash equivalents, and marketable securities · Q2-2026 | $129M |
Guidance
Revenue guidance raised to $114-117M from prior range
Revenue guidance raised; strong demand and margin expansion.
Risks flagged
Net loss widening; operating expenses growing faster than revenue.
“Net loss $19.3M vs $13.6M; operating expenses +37%.”
11 May 20268-K · 2.02Total revenue $26M (+29% y/y); Product revenue $20M (+29% y/y); Subscription revenue $6M (+29% y/y); Guidance: FY2026 revenue guidance raised to $112M-$116M (26-30% growth)earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $27M | +29% y/y |
| Product revenue · Q1-2026 | $20M | +29% y/y |
| Subscription revenue · Q1-2026 | $6M | +29% y/y |
| Gross margin · Q1-2026 | 87.0% | |
| Active accounts · Q1-2026 | 680 | |
| Net loss · Q1-2026 | $-20M | +54% y/y |
| Adjusted EBITDA loss · Q1-2026 | $-11M | +3% y/y |
| Cash, cash equivalents, and marketable securities · Q1-2026 | $141M |
Guidance
FY2026 revenue guidance raised to $112M-$116M (26-30% growth)
Ceribell raised FY2026 revenue guidance reflecting strong demand and execution.
Risks flagged
Increasing net loss and operating expenses, including legal costs from patent litigation, may pressure cash runway.
“Net loss increased to $19.7M from $12.8M; operating expenses rose 36% to $43.9M, partly due to legal costs for patent infringement suit.”
Dependence on third-party manufacturers in China and Vietnam introduces supply chain risk.
“Risk factors mention reliance on third-party manufacturers and suppliers in China and Vietnam.”
11 May 202610-QNet Loss $-20M; Accumulated Deficit $-240Mopen
Figures in the filing · each found in the filing text
| Net Loss · Q1-2026 | $-20M | |
| Accumulated Deficit · 2026-03-31 | $-240M |
Risks flagged
Tariff and Supply Chain Risk
“We rely on manufacturing facilities and third-party suppliers outside the United States, including in China and Vietnam, for the primary assembly and inspection of our Wearables and for a significant portion of our components.” · word for word
Reimbursement Risk
“In August 2023, CMS approved an NTAP under the Medicare inpatient prospective payment system for our newest Clarity algorithm, effective October 1, 2023. The NTAP designation for a product lasts for no more than three years for a specific indication.” · word for word
Product Liability Risk
“The production and sale of defective products could adversely affect our business, financial condition, results of operations, and prospects.” · word for word
24 Feb 202610-KNet Loss $-53M; Accumulated Deficit $-220Mopen
Figures in the filing · each found in the filing text
| Net Loss · FY2025 | $-53M | |
| Accumulated Deficit · FY2025 | $-220M |
Risks flagged
History of net losses and expected continued losses
“We have incurred net losses since inception, and we expect to incur additional substantial losses in the foreseeable future.” · word for word
Tariff and supply chain risk
“Tariffs on products imported from China could adversely affect our suppliers’ operations, potentially causing disruptions or requiring us to transition to alternative manufacturers.” · word for word
24 Feb 20268-K · 2.02Total Revenue $89M (+36% y/y); Product Revenue $67M (+34% y/y); Subscription Revenue $22M (+41% y/y); Guidance: 2026 revenue $111M-$115M (25-29% growth)earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $89M | +36% y/y |
| Product Revenue · FY2025 | $67M | +34% y/y |
| Subscription Revenue · FY2025 | $22M | +41% y/y |
| Gross Margin · FY2025 | 88.0% | |
| Active Accounts · Q4-2025 | 647 | |
| Net Loss · FY2025 | $-53M | +32% y/y |
Guidance
2026 revenue $111M-$115M (25-29% growth)
Strong growth trajectory with continued momentum expected
Risks flagged
Net losses continue despite strong revenue growth
“Net loss of $53.4 million in 2025, up from $40.5 million in 2024”
Operating expenses growing faster than revenue
“Operating expenses increased 42% vs revenue growth of 36%”
5 Jan 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
No new risk signals; regulatory designation is positive.
2 Jan 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
No material risk; routine board change.
4 Nov 20258-K · 2.02Total revenue $23M (+31% y/y); Product revenue $17M (+28% y/y); Subscription revenue $6M (+44% y/y); Guidance: FY2025 revenue guidance raised to $87-89M from prior rangeearningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $23M | +31% y/y |
| Product revenue · Product · Q3-2025 | $17M | +28% y/y |
| Subscription revenue · Subscription · Q3-2025 | $6M | +44% y/y |
| Gross margin · Q3-2025 | 88.0% | |
| Net loss · Q3-2025 | $-14M | |
| Total active accounts · Q3-2025 | 615 | |
| Cash, cash equivalents, and marketable securities · Q3-2025 | $169M |
Guidance
FY2025 revenue guidance raised to $87-89M from prior range
Raised full-year revenue guidance reflecting strong commercial execution and adoption
Risks flagged
Operating expenses growing faster than revenue (39% vs 31%), leading to net loss
“Operating expenses increased 39% to $34.6 million, while revenue grew 31%”
Dependence on China/Vietnam manufacturing and tariff exposure
“Manufacturing of a substantial number of our product components and their assembly in China and Vietnam” · word for word
4 Nov 202510-QCeriBell reported Q3 2025 results with 31% revenue growth, improved gross margins, but increased net loss due to higher operating expenses.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $23M | +31% y/y |
| Product revenue · Q3-2025 | $17M | +28% y/y |
| Subscription revenue · Q3-2025 | $6M | +44% y/y |
| Gross margin · Q3-2025 | 88.0% | |
| Net loss · Q3-2025 | $-13M | +29% y/y |
| Active accounts · Q3-2025 | 600 |
Risks flagged
Patent infringement litigation
“General and administrative expenses increased due to costs associated with intellectual property enforcement activities, including a new patent infringement claim initiated in July 2025.”
Continued operating losses
“We have incurred operating losses since the commencement of our operations and we expect to continue to incur losses as we grow and continue the transition to operating as a public company.” · word for word
Dependence on new account acquisition and utilization
“Our revenue fluctuates primarily based on the number of active accounts and the volume of headband usage.” · word for word
CeriBell, Inc. — questions
- What did CeriBell, Inc. file recently?
- 15 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-10 — Quarterly report filed with updated financials; no earnings beat or miss stated.
Every figure on this page comes from CeriBell, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.